Genome-Edited T Cell Therapies. (2022)
Attributed to:
Phase 1 evaluation of CRISPR-CAR gene edited T cells in relapsed refractory B cell acute lymphoblastic leukaemia
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.hoc.2022.03.006
PubMed Identifier: 35773047
Publication URI: http://europepmc.org/abstract/MED/35773047
Type: Journal Article/Review
Volume: 36
Parent Publication: Hematology/oncology clinics of North America
Issue: 4
ISSN: 0889-8588